LPL Financial LLC Has $81,000 Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

LPL Financial LLC increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 23.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,567 shares of the biopharmaceutical company’s stock after purchasing an additional 5,080 shares during the period. LPL Financial LLC owned approximately 0.05% of Puma Biotechnology worth $81,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. grew its holdings in shares of Puma Biotechnology by 8.0% during the fourth quarter. Sei Investments Co. now owns 311,661 shares of the biopharmaceutical company’s stock worth $951,000 after buying an additional 23,179 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company’s stock worth $2,893,000 after acquiring an additional 73,833 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Puma Biotechnology by 32.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 487,368 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 118,913 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Puma Biotechnology by 16.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 285,679 shares of the biopharmaceutical company’s stock valued at $871,000 after purchasing an additional 39,984 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Puma Biotechnology by 19.5% in the fourth quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company’s stock worth $1,012,000 after purchasing an additional 54,150 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Down 3.1 %

PBYI stock opened at $3.08 on Friday. The business’s fifty day moving average price is $3.12 and its two-hundred day moving average price is $3.03. The stock has a market capitalization of $152.80 million, a price-to-earnings ratio of 6.42 and a beta of 1.34. Puma Biotechnology, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $5.26. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. On average, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PBYI shares. StockNews.com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.